Previous close | 0.5104 |
Open | 0.5224 |
Bid | 0.5283 x 200 |
Ask | 0.6756 x 200 |
Day's range | 0.5200 - 0.5494 |
52-week range | 0.4010 - 2.3200 |
Volume | |
Avg. volume | 7,132,018 |
Market cap | 256.912M |
Beta (5Y monthly) | 1.29 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor-mediated killing of ULBP6-expressing cancer cells through enhanced effector function SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating
Built upon peer-reviewed published science, the Historical Matches feature weaves customers’ ancestral connections into the story of human history and migrationSOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released an exciting new feature for 23andMe+ Premium and Total Health members, that uncovers DNA connections to 335 unique historical individuals, from medieval Vikings to late Stone Ag
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMeSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models know